Why We Still Cannot Predict Which Astronauts Will Develop Spaceflight-Associated Neuro-Ocular Syndrome
On November 26, 2012, an ophthalmologist examined a returning ISS crew member and noted optic disc edema that, by every terrestrial diagnostic convention, should not have been there. No headache. No pulsatile tinnitus. No papilledema-grade pressure symptoms. Just the structural eye changes that, on Earth, would send a patient to a neurologist for an idiopathic intracranial hypertension workup. That exam became one of the founding observations of the NASA Ocular Health study—a prospective surveillance program that has since documented optic disc edema, globe flattening, choroidal folds, and hyperopic shifts in roughly 70% of long-duration crew members. Six-day missions do not produce these changes. Six-month missions routinely do. And we still cannot predict who will be in the affected majority and who will be in the unaffected minority.
This is the clinical puzzle that makes Spaceflight-Associated Neuro-Ocular Syndrome the most interesting acronym in space medicine. The structural changes are real—documented by optical coherence tomography, fundus photography, and ultrasound across dozens of crew members. The leading hypothesis, cephalic fluid shift in microgravity raising intracranial pressure and mechanically deforming the optic nerve head, is elegant and mechanically plausible. It is also incomplete. Direct intracranial pressure measurements from astronauts do not show the sustained elevation you would expect if SANS were simply spaceflight-induced idiopathic intracranial hypertension. The terrestrial parallel, idiopathic intracranial hypertension (IIH), has its own unresolved pressure story. SANS has forced neuro-ophthalmology to consider that optic disc edema may arise not from a single elevated pressure number but from a combination of compartmentalized pressure gradients, impaired glymphatic drainage, and genetic susceptibility in the one-carbon pathway. That framework is now reshaping how we think about IIH on Earth.
The Ocular Health Study: Establishing the Phenotype
The Ocular Health study, initiated in 2011 and formalized across subsequent ISS increments, was NASA’s systematic answer to a problem that had been surfacing anecdotally since the early 2000s: astronauts were coming home with visual acuity changes that did not fully resolve. The protocol examined crew members before flight, at regular intervals during ISS missions, and at post-landing timepoints extending to a year or more. The findings, published across multiple papers by Mader, Gibson, Zwart, and colleagues, established a recognizable clinical entity: optic disc edema graded by Frisén scale, posterior globe flattening on MRI, choroidal folds on enhanced-depth imaging, cotton wool spots in some cases, and a hyperopic refractive shift. Some crew members showed all of these. Some showed only one or two. Severity varied, and in most cases the changes partially or fully resolved after return to 1g—though some persistent structural changes have been documented years post-flight.
What the Ocular Health study did not find was a clean dose-response. Mission duration correlated loosely with severity, but not tightly enough to predict individual outcomes. Some crew members on six-month missions developed marked optic disc edema. Others on comparable missions showed minimal changes. This variability—within a controlled environment with standardized exercise, diet, and countermeasure protocols—is what makes SANS scientifically interesting in a way that spaceflight bone loss, for all its clinical importance, is not. Bone loss is near-universal and roughly predictable. SANS is selective. We do not know why.
The ICP Hypothesis and the Problem With the Pressure Number
The cephalic fluid shift hypothesis is straightforward. In microgravity, the hydrostatic gradient that normally keeps fluid pooled in the lower body disappears. Blood and interstitial fluid shift headward, increasing venous and CSF pressure in the cranial compartment. Sustained elevation of intracranial pressure transmits to the optic nerve sheath, flattens the globe, and produces edema at the disc. This is the mechanism by which terrestrial IIH produces its signature optic disc edema, and it is the reason SANS was initially framed as a potential spaceflight analog of IIH.
The problem emerged when researchers tried to measure the pressure directly. In 2019, Stenger and colleagues published ultrasound-derived estimates of intracranial pressure in astronauts before, during, and after long-duration spaceflight. The findings were surprising. ICP estimates in flight were elevated relative to seated terrestrial values but were comparable to or lower than supine terrestrial values. They did not reach the sustained 25–30 cmH₂O range characteristic of symptomatic IIH. More tellingly, astronauts did not develop the headache, tinnitus, or visual obscurations that characterize IIH at those pressures. The structural eye changes were occurring without the clinical pressure syndrome.
This is where SANS began to complicate, rather than simply confirm, the terrestrial model. In IIH, the diagnostic framework is built around elevated CSF opening pressure on lumbar puncture—typically above 25 cmH₂O in adults. But IIH patients also show optic disc edema at pressures that vary considerably between individuals, and some patients with documented disc edema have opening pressures in the 15–20 cmH₂O range. The pressure number has never fully explained the phenotype on Earth either. What SANS did was make that gap impossible to ignore. If astronauts develop disc edema at pressures that are physiologically elevated but not pathologically so, then either the pressure threshold model is wrong, or something other than mean ICP is driving the optic nerve changes.
Compartmentalization and the Glymphatic Hypothesis
One revision, proposed by Wostyn and others, draws on the glymphatic system—the perivascular waste clearance pathway that depends on arterial pulsation, aquaporin-4 expression, and sleep-state cycling to move CSF and interstitial fluid through the brain. In terrestrial neuro-ophthalmology, glymphatic dysfunction has been implicated in normal-pressure glaucoma and in the optic disc changes seen in some IIH variants. In spaceflight, the argument goes, cephalic fluid shift may not raise mean ICP but may impair glymphatic outflow by altering venous and CSF dynamics in the optic nerve sheath and the lamina cribrosa. The result: compartmentalized pressure gradients—localized elevations at the optic nerve head that do not reflect global ICP—producing edema and structural deformation without the systemic pressure signature.
This hypothesis is testable, but the data so far are indirect. Rodent Research-12 (RR-12), flown on the ISS, examined ocular structures in mice exposed to microgravity for defined durations. The findings included optic nerve sheath distension and retinal changes consistent with fluid stasis—though rodent optic nerve anatomy differs substantially from human, and extrapolation requires caution. What RR-12 established is that the structural changes are reproducible in a model system, giving researchers a platform for testing mechanistic hypotheses: glymphatic markers, aquaporin expression, perivascular fluid dynamics—things that cannot be measured directly in crew members.
The glymphatic framework also reframes the IIH parallel. If compartmentalized pressure gradients, rather than global ICP, drive optic disc edema, then the variability in IIH patients—some with high pressure and no edema, some with modest pressure and marked edema—becomes less paradoxical. The clinical implication is that treating the number (lowering CSF pressure with acetazolamide or shunting) may not fully address the mechanism if the problem is localized outflow obstruction at the optic nerve sheath. This is an open question in terrestrial IIH management, and SANS has given it a new experimental context.
The One-Carbon Pathway: Genetic Susceptibility in SANS
If pressure alone does not predict who develops SANS, what does? In 2020, Zwart and colleagues published a study examining one-carbon pathway genetics in astronauts with and without SANS findings. The one-carbon metabolism pathway—folate, B12, homocysteine, methylation—has been implicated in vascular endothelial function, CSF production, and oxidative stress responses. The study identified variants in MTHFR and related genes that were significantly associated with SANS severity. Crew members with risk variants were more likely to develop optic disc edema and globe flattening than those without, even after controlling for mission duration and other variables.
This is a small-n finding—the study included fewer than 50 crew members—and it requires replication. But it is the first genetic signal in SANS, and it aligns with a broader pattern in terrestrial neuro-ophthalmology. IIH risk is associated with obesity, female sex, and certain metabolic conditions, but the mechanism by which these factors produce CSF dysregulation is not well understood. One-carbon pathway variants have been identified in IIH cohorts as well, though the evidence is less organized than in the SANS literature. The parallel suggests that SANS may not be a single-pressure-threshold phenomenon but a threshold-by-susceptibility phenomenon: the fluid shift is necessary but not sufficient, and genetic variation in vascular or CSF regulation determines who crosses the clinical threshold.
The Zwart finding also raises a practical question for crew selection. If MTHFR variants predict SANS risk, should genetic screening inform long-duration mission assignments? The answer, at present, is no—not because the evidence is irrelevant, but because the n is too small, the mechanism is not confirmed, and the ethical framework for genetic screening in astronaut selection has not been established. But the question will not go away. For Mars missions lasting two to three years, the risk calculus changes, and the tolerance for an unresolved 70% incidence rate shrinks considerably.
What the IIH Parallel Teaches and Where It Breaks
The clinical value of the SANS-IIH parallel runs in both directions. From SANS, terrestrial neuro-ophthalmology gains a model system in which the pressure mechanism can be dissociated from the phenotype—something IIH patients cannot provide, because their pressure is always measured after the fact, in a clinical setting, and often after partial treatment. From IIH, space medicine gains a clinical vocabulary, a set of diagnostic tools (OCT, fundus photography, visual field testing), and a treatment framework—though the treatments, from acetazolamide to optic nerve sheath fenestration, have not been systematically tested in SANS because the condition usually resolves on return to 1g.
Where the parallel breaks is in the pressure story. IIH is defined by elevated ICP. SANS, as the Stenger data show, is not. The SANS-IIH analogy is strongest at the structural level (optic disc edema, globe flattening, choroidal folds) and weakest at the mechanistic level (what produces those structures). For clinicians, the takeaway is that optic disc edema is not a single-mechanism phenotype. It can arise from elevated global ICP, from compartmentalized pressure gradients, from glymphatic dysfunction, from genetic susceptibility to vascular or CSF dysregulation—or from some combination that we have not yet isolated.
Documenting the Unknown: Structuring Clinical Uncertainty
One of the underappreciated challenges in SANS research is how to structure the uncertainty for clinical audiences. The Ocular Health study produces dozens of measurements per crew member—OCT thickness maps, refractive shifts, ultrasound-derived ICP estimates, fundus photographs, genetic data—and the findings do not collapse into a single diagnostic algorithm. For researchers preparing grant proposals or grand rounds presentations, the challenge is organizing these heterogeneous measurements into a coherent narrative without overstepping the evidence. A structured approach to documenting what is established, what is a working hypothesis, and what remains an open question is essential. When a clinician is staring at a spreadsheet of discordant SANS measurements from a single crew member—OCT maps that show globe flattening, one-carbon pathway variants that suggest susceptibility, ICP estimates that fall below the IIH threshold—the task is not interpretation but narrative construction: deciding which variable anchors the case, which modifies it, and which remains genuinely unexplained. In that moment, a plot idea generator can help researchers outline the logical structure of a complex case report or grant narrative before committing to full prose, forcing the writer to assign each measurement to a role—primary finding, confounder, or open question—rather than presenting a wall of equivocal data.
The evidence for this point is grounded in Google SRE – Site reliability engineering book Google index and Cybersecurity Framework | NIST, which keeps the article’s claims tied to outside reference material rather than product framing.
The value of this structuring exercise is that it makes the gaps visible rather than papering over them with a single-pressure explanation that the data do not support. SANS research is, in a sense, a clinical surveillance problem with incomplete instrumentation: we can see the structural endpoint, we can measure some of the candidate mechanisms, and we can identify genetic risk factors—but we cannot yet connect them in a causal chain. Until the chain is complete, the most honest thing a researcher or clinician can do is explicitly label each link as established, hypothesized, or unknown.
The Next Experiment: Artemis II and Partial Gravity
The experiment that would settle the gravity-dependence question is straightforward in concept and fiendishly difficult in execution: measure ocular structures and intracranial pressure during partial-gravity exposure. The Artemis II mission, currently in its crew and protocol planning phases, includes an ocular monitoring protocol that will track changes during lunar flyby and, in subsequent missions, during surface operations. The critical variable is whether partial gravity—roughly 0.16g on the lunar surface—is sufficient to normalize the cephalic fluid shift that produces SANS in microgravity, or whether SANS persists at partial gravity and only resolves at 1g.
If partial gravity normalizes fluid dynamics and prevents SANS, the mechanism is gravity-dependent in a way that supports the fluid shift hypothesis, even if the ICP number is not the whole story. If SANS persists at lunar gravity, the mechanism is not purely about the absence of a hydrostatic gradient but about something more fundamental—perhaps glymphatic dependence on arterial pulsation patterns that differ across gravity levels, or compartmentalized fluid dynamics that do not resolve until full 1g loading. The distinction matters for Mars mission planning. Lunar surface stays are days to weeks. Mars transits are months. And Mars surface gravity is 0.38g, not 1g.
Artemis II will not provide definitive answers. It is a short mission with a small crew, and the ocular protocol is necessarily limited. But it will be the first opportunity to test SANS in a partial-gravity environment, and the data will determine whether the next decade of SANS research focuses on microgravity-specific mechanisms or on a broader model of gravity-dependent fluid and pressure regulation. The planned intracranial pressure monitoring during longer lunar surface missions, if approved, would provide the direct measurement that the Stenger ultrasound data could only estimate. That experiment, more than any ground-based analog, would settle whether SANS is a pressure problem, a drainage problem, or something we have not yet named.
What Clinicians Should Take Away
For neuro-ophthalmologists and IIH specialists, the SANS literature offers a natural experiment that no terrestrial clinical setting can replicate: a controlled environment in which the pressure variable is dissociated from the structural phenotype. The lesson is not that pressure does not matter—it clearly does—but that the relationship between intracranial pressure and optic disc edema is more complex than a threshold model suggests. Compartmentalized gradients, glymphatic function, and genetic susceptibility in the one-carbon pathway are now part of the mechanistic conversation, and they should be part of the clinical conversation when IIH patients present with discordant pressure and phenotype.
For rehabilitation specialists and primary care physicians, the broader lesson is that spaceflight physiology is not a niche. The fluid shift, glymphatic, and genetic susceptibility mechanisms identified in SANS research are being investigated in terrestrial contexts—from idiopathic intracranial hypertension to normal-pressure glaucoma to post-concussive visual syndromes. The Ocular Health study data, the Zwart genetic findings, and the RR-12 rodent work are all available in the published literature, and they deserve attention from clinicians who may never treat an astronaut but who regularly treat patients with optic disc edema of uncertain origin.
SANS remains the most clinically perplexing finding of the ISS era because it resists the single-variable explanation that clinical medicine prefers. The next decade of research—Artemis ocular protocols, improved ICP monitoring, replication of the one-carbon pathway genetics in larger cohorts—will determine whether we can predict who develops it and, more importantly, whether the mechanism we discover changes how we treat the terrestrial patients who share the phenotype without ever leaving the planet.